$MDGL has seen significant gains recently, trading close to $300, up from below $70 two years ago, following the successful reporting of Phase 3 results. The stock's market capitalization is approximately $7 billion, attributed to its MASH pipeline. Investors have noted the stock's performance, with some closing positions after substantial profits. The stock has risen around 350% since the Phase 3 results announcement in 2022. In contrast, $VKTX, another biotech company focused on obesity treatments, is valued at over $8 billion and is expected to release oral data soon, which could impact its Phase 2 trial outcomes. Both companies are seen as key players in the MASH and obesity treatment sectors, with traders highlighting their potential for further growth. $MDGL's recent performance has been attributed to its cash position and profitability, despite challenges in the market.